FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
FDA placed a clinical hold on VYNE's VYN202 Phase 1b study. Hold due to testicular toxicity observed in dogs during toxicity studies. VYNE has suspended screening, enrollment, and dosing related to VYN202. No serious adverse events reported in the Phase 1b study so far. VYNE continues Phase 2b trial of repibresib, unrelated to VYN202.
View signal analysis